Does Novartis Cancer Agreement Mean That Transgenomic Might Be Rounding a Corner? | GenomeWeb

Around this time last year, Transgenomic was putting the finishing touches on a cost-cutting strategy that would claim 80 jobs — or a quarter of its staff — including Gregory Duman, the CFO.

The move, which would cost the company between $3 million and $4 million in one-time restructuring charges, was designed to off-set lackluster sales of its Wave instruments — which was symptomatic of a deepening slump felt by other companies in pharmacogenomics.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.

In PLOS this week: nasal microbial communities in asthma patients; sequencing-based way to detect, track schistosomiasis; and more.

The New York Times speaks with Vanderbilt's John Anthony Capra about Neanderthal genes in modern humans.

A draft guidance from the FDA suggests the agency wants to more tightly control gene-edited animals, according to Technology Review.

Researchers were among this weekend's protesters bemoaning the new US administration, Vox reports.